Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
AD

NASDAQ · ADIL

Adial Pharmaceuticals, Inc.

Healthcare · Biotechnology

$5.05

Up+$1.34 (+36.12%)

Updated Nov 4, 2026, 9:03 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.43M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$1.31 – $9.53
Volume
99.65K
Avg. volume
28.85K

Price performance · ADIL

ADIL price history

1M range · 0 trading sessions · Daily adjusted prices

ADIL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ADIL news

The latest Smart Investors Daily articles mentioning ADIL.

Stock researchCompany · Overview

ADIL research

Overview

Company profile and research snapshot.

Company profile

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ADIL recent ratings
DateFirmRatingTarget
Aug 3, 2026Alliance Global PartnersBuy—
Jun 15, 2026LUCID CAPITAL MARKETSBuy—
Sep 30, 2025Maxim GroupBuy—
Nov 14, 2024Rodman & RenshawBuy—
Jul 11, 2023Brookline CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock to begin trading on Nasdaq under the ticker symbol “AZR” New executive leadership team with deep experience spanning drug development and clinical expertise in AhR biology and inflammatory bowel disease Phase 1 clinical trial initiation of AT177 expected in the first half of 2027 LOS ANGELES, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASD

Yahoo · Oct 26, 2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Seasoned public company CFO with deep autoimmune disease experience has helped raise more than $1 billion over a 20+ year biotech career Will lead the Company’s finance organization and capital strategy as it transitions to Azora Therapeutics and advances AT177 toward the clinic GLEN ALLEN, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammato

Yahoo · Oct 16, 2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027 GLEN ALLEN, Va., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) ("Adial" or the "Company"), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By